Sonoma Biotherapeutics

Sonoma Biotherapeutics is a privately held company developing regulatory T cell (Treg) therapies for autoimmune and degenerative diseases.

Sonoma is inventing the future of living therapies for autoimmune disease — safe, effective treatments as unique as each individual patient.

Sonoma Biotherapeutics was founded in 2019 by Jeffrey Bluestone, Fred Ramsdell, Alexander Rudensky and Qizhi Tang. The company is headquartered in South San Francisco, California, with an office in Seattle, Washington.

 

Sonoma Bio leverages the properties of regulatory T cells (Treg) to create living cell therapies that restore the immune system back to its balanced, fully functioning state.

 

Sonoma's best-in-class Treg therapies possess multiple therapeutic effects, within a single medicine, helping overcome the complex and multifaceted nature of autoimmune and inflammatory disease.

 

Sonoma Bio's treg cell therapy discovery programs are also underway targeting other autoimmune and inflammatory diseases. 

 

Sonoma Bio is backed by Ally Bridge Group, ArrowMark, 8VC, Lyell Immunopharma, ARCH Venture Partners, Avidity Partners, Casdin Capital, Fidelity Management & Research Company, and others. The company raised $265M in Series B round on Aug 04, 2021. This brings Sonoma Bio's total funding to $305M to date

 

 

  • Year founded: 2019
  • Funding Info: $305M over 2 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: South San Francisco
  • State: California
  • Country: United States
Related businesses